Fresolimumab

Generic Name: Fresolimumab

Brand Names: -

Drug Type: Biotech

Chemical Formula: -

CAS Number: 948564-73-6

Unique Ingredient Identifier: 375142VBIA

Background: Fresolimumab has been used in trials studying the treatment of Primary Brain Tumors, Metastatic Breast Cancer, Diffuse Systemic Sclerosis, Pleural Malignant Mesothelioma, and Primary Focal Segmental Glomerulosclerosis.

Associated Conditions: -

Associated Therapies: -

Clinical Trials

pmc.ncbi.nlm.nih.gov

·

13 years ago

Emerging drugs for myelofibrosis

Myelofibrosis (MF) is a severe myeloproliferative neoplasm characterized by dysregulated JAK/STAT signaling, leading to symptoms like splenomegaly and anemia. Ruxolitinib, a JAK1/JAK2 inhibitor, is approved for MF treatment, improving spleen size and symptoms but not reversing bone marrow fibrosis. Ongoing research explores combination therapies and new agents targeting anemia and fibrosis.

Related Clinical Trials:

Ruxolitinib and Lenalidomide for Patients With Myelofibrosis

Efficacy and Safety of Simtuzumab in Adults With Primary, Post Polycythemia Vera or Post Essential Thrombocythemia Myelofibrosis

Ruxolitinib and Pomalidomide Combination Therapy in Patients With Primary and Secondary MF

Panobinostat and Ruxolitinib in Primary Myelofibrosis, Post-polycythemia Vera-myelofibrosis or Post-essential Thrombocythemia-myelofibrosis

COntrolled MyeloFibrosis Study With ORal JAK Inhibitor Treatment: The COMFORT-I Trial

Controlled Myelofibrosis Study With Oral Janus-associated Kinase (JAK) Inhibitor Treatment-II: The COMFORT-II Trial

Phase III Study of SAR302503 in Intermediate-2 and High Risk Patients With Myelofibrosis

Study of Pomalidomide in Persons With Myeloproliferative-Neoplasm-Associated Myelofibrosis and RBC-Transfusion-Dependence

Exploratory Phase II Study of INC424 Patients With Primary Myelofibrosis (PMF) or Post Polycythaemia Myelofibrosis (PPV MF) or Post Essential Thrombocythaemia Myelofibrosis (PET-MF)

Open Label Ruxolitinib (INCB018424) in Patients With Myelofibrosis and Post Polycythemia Vera/Essential Thrombocythemia Myelofibrosis

Ruxolitinib (INCB018424) in Participants With Primary Myelofibrosis (PMF), Post Essential Thrombocythemia-myelofibrosis and Post Polycythemia Vera-myelofibrosis (PPV-MF)

Study of Ruxolitinib (INCB018424) Sustained Release Formulation in Myelofibrosis Patients

Alternative Dosing Strategy of Ruxolitinib in Patients With Myelofibrosis

Phase II, Open Label, Single Arm Study of SAR302503 In Myelofibrosis Patients Previously Treated With Ruxolitinib

Extension Study Evaluating the Long Term Safety and Efficacy Study of CYT387 in Primary Myelofibrosis (PMF) or Post-polycythemia Vera (PV) or Post-essential Thrombocythemia (ET)

Safety Study Evaluating Twice-Daily Administration of Momelotinib in Primary Myelofibrosis or Post-Polycythemia Vera or Post-Essential Thrombocythemia Myelofibrosis

A Study of LY2784544 in Participants With Myeloproliferative Neoplasms

Study of LY2784544 Testing Alternative Dosing in Participants With Myeloproliferative Neoplasms

Anti-TGF-beta Therapy in Patients With Myelofibrosis

A Study of Low Dose Interferon Alpha Versus Hydroxyurea in Treatment of Chronic Myeloid Neoplasms

Prev
1
Next

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy